TB-500 cycle length: how long protocols actually run

Last updated 2026-07-25

How long is a typical TB-500 cycle?

Most protocols you'll see from compounding sources and peptide clinics run a TB-500 cycle for 4 to 8 weeks, dosed once or twice weekly, followed by a break or a drop to a lower maintenance dose. That's the practical answer. It is not a number that comes from a human clinical trial with a defined endpoint. The honest caveat: there is no published randomized trial in humans that tested TB-500 cycle length against outcome and found an optimal duration. A recent review in the Journal of the American Academy of Orthopaedic Surgeons' Global Research & Reviews looked at therapeutic peptides used in orthopaedics, including regenerative peptides like TB-500 and BPC-157, and flagged the gap between what's marketed and what's been formally studied in humans ^[1]. A 2026 primer in The American Journal of Sports Medicine aimed at orthopaedic and sports medicine physicians makes a similar point: injectable peptide therapy is being used clinically well ahead of the evidence base that would normally justify a dosing standard ^[2]. So when someone tells you '6 weeks on, 4 weeks off' is the correct cycle, what they're really repeating is a compounding-pharmacy convention, not a study result. It's a reasonable starting framework. It isn't science in the way a drug label's dosing section is science.

Is TB-500 the same as thymosin beta-4?

No, and mixing these up is where a lot of bad information starts. Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein found in nearly every mammalian cell, involved in actin regulation and tissue repair signaling. TB-500 is a synthetic peptide sold in the research and gray markets that is supposed to mimic the active region of Tβ4, but it isn't a simple copy of the full protein. Analytical chemistry work has actually gone after this distinction directly. One study characterized the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500 products, specifically because regulators and testers needed to know what molecule was actually showing up in vials sold under that name ^[3]. Another paper developed a method to simultaneously quantify TB-500 and its metabolites in vitro and in rats using UHPLC-Q-Exactive Orbitrap mass spectrometry, screening for wound healing activity along the way ^[4]. That kind of work exists because 'TB-500' as sold is not a single, settled chemical entity in the way an FDA-approved drug is; it needs metabolite tracking and fragment identification precisely because the commercial product and the native protein aren't interchangeable. If you want the fuller breakdown of what's structurally different and why it matters for dosing assumptions, see TB4 peptide vs TB500.

What does a standard TB-500 cycle protocol look like?

A typical structure quoted in peptide-use circles looks like this: a loading phase of roughly 4-6 weeks, dosing 2-2.5 mg two or three times per week, then either stopping entirely or dropping to a lower maintenance dose (often 2-2.5 mg once weekly or every other week) for another 4-8 weeks depending on what's being addressed.

That table is not a citation of a study. It's a summary of the convention you'll find repeated across clinics and forums. Nobody has published a trial comparing 4-week to 8-week to 12-week cycles in humans and measuring recovery outcomes. For the mechanics of actually administering doses within a cycle, see TB-500 how to inject and TB-500 injection sites.

How long does it take to see effects during a cycle?

People commonly report noticing subjective changes (less stiffness, easier range of motion) somewhere in the 2-4 week range into a cycle, with more meaningful change reported by week 6-8. That's self-report territory, not measured outcome data from controlled human trials. What we actually have is preclinical and analytical work. The wound-healing screening done alongside the metabolite quantification study used in vitro assays and rats, not humans, and the timeline in that model doesn't map directly onto a human tendon or ligament injury timeline ^[4]. A 2026 Sports Medicine (Auckland) review on the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is explicit that the evidence for peptides like TB-500 is overwhelmingly preclinical, and that translating rodent or in vitro timelines into a human dosing calendar is not something the current literature supports with confidence ^[5]. So if someone promises a specific week where you'll 'feel it kick in,' that's pattern-matching from anecdote, not a validated pharmacokinetic timeline.

Should you cycle TB-500 with breaks, or run it continuously?

Most protocols include a break, typically 4-6 weeks off after a loading and maintenance run, before considering another cycle. The stated logic is to avoid receptor or pathway habituation and to reassess whether continued use is doing anything. There's no human trial testing continuous versus cycled dosing for TB-500 specifically. The rationale for breaks is borrowed from how other peptide and hormone protocols are commonly run, applied to TB-500 by analogy rather than by direct evidence. A 2026 Frontiers in Aging review on therapeutic peptides in gerontology discusses mechanisms and applications for healthy aging generally, and notes that dosing schedule optimization across peptide classes remains an active mechanistic question rather than a solved one ^[6]. That's a broader peptide-class statement, not TB-500-specific proof of an ideal cycle-break ratio, but it reflects the state of the field: schedule questions are still being worked out even for peptides with more research attention than TB-500 gets.

Does cycle length change if you're stacking with BPC-157?

In practice, no. TB-500 is not sold as a standalone product. It's dispensed as a BPC-157/TB-500 blend, and cycle length recommendations you'll see are for that combined product, not an isolated TB-500 run. This matters for two reasons. First, if you're comparing 'TB-500 cycle length' advice from different sources, check whether they're actually describing a blend protocol or a hypothetical mono-product protocol, because the two get conflated constantly online. Second, neither half of that blend has a controlled human trial establishing an optimal combined cycle length. The orthopaedic literature reviews mentioned above discuss both peptides as part of the same emerging, mostly preclinical category ^[1][2]. If you're looking at where to source a legitimate blend and want the provider-reviewed route rather than an anonymous vial, that's covered on TB-500 for sale, which walks through what a compounding-pharmacy-fulfilled blend actually looks like versus unregulated sellers.

How is a TB-500 cycle actually regulated or sourced legally?

TB-500 is not an FDA-approved drug. You won't find it in the Drugs@FDA database of approved products ^[7]. It also isn't on FDA's current list of bulk drug substances that compounding pharmacies are permitted to use under Section 503A of the Federal Food, Drug, and Cosmetic Act ^[8], nor is it on the parallel 503B bulks list for outsourcing facilities ^[9]. Section 503A of the FD&C Act (21 U.S.C. 353a) allows licensed pharmacists to compound drugs for individual patients under specific conditions, and FDA maintains the bulk substances list referenced in 21 CFR 216.23 to define what can legally go into a 503A compound ^[10][11]. A substance not on that list, or not an FDA-approved active ingredient, doesn't automatically become legal to compound just because a prescriber writes an order for it. This is the regulatory gray zone TB-500 sits in, and it's a big part of why cycle length guidance is coming from clinics and compounders working somewhat informally rather than from an approved product label. For a fuller look at the evidence landscape and what's actually published, start at TB-500.

Do athletes need to worry about detection during a cycle?

Yes. TB-500 and thymosin beta-4-derived peptides are prohibited under the World Anti-Doping Agency's Prohibited List, and there is a substantial body of analytical chemistry work built specifically to catch it in doping control, which tells you regulators consider it a real detection target, not a theoretical one. A 2012 Journal of Chromatography A study developed a liquid chromatography-mass spectrometry method to detect TB-500 in equine urine and plasma ^[12]. Human-focused work has followed the same path: a 2014 review in the Journal of Pharmaceutical and Biomedical Analysis covered analytical approaches for detecting emerging therapeutics and non-approved drugs, including TB-500, in human doping controls ^[13]. Other papers have gone deep on adsorption behavior of TB-500 and related peptides during sample handling ^[14], solid-phase extraction methods for isolating small bioactive peptides from urine ^[15], and in vitro metabolism models built specifically to understand how small peptide hormones like TB-500 break down in the body for testing purposes ^[16]. If you compete under WADA or a WADA-code signatory, cycle length is close to irrelevant to your risk calculation. Any use inside a testable window is the exposure, more than how long you ran it.

What happens if you run a cycle longer than 8 weeks?

Nobody has published human safety data on extended TB-500 cycles beyond the usual 8-week window, so anything past that is unstudied territory, not a proven-safe extension. The closest thing to a formal safety look is the 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, which frames the safety picture for peptides like TB-500 as thin and largely extrapolated from animal or in vitro work rather than long-duration human dosing studies ^[5]. That review's framing is a caution flag, not a green light: absence of documented harm at longer durations is not the same as documented safety. If you're going to run longer than the common 6-8 week window anyway, the more defensible approach is smaller doses, closer symptom tracking, and a hard stop if you notice anything unexpected, rather than assuming length scales safety linearly with benefit.

How do you know when to stop a cycle early?

Stop early if you notice unexpected injection site reactions, systemic symptoms (fever, unusual fatigue, swelling beyond the injection area), or simply no subjective change by the midpoint of your planned loading phase. There's no lab test or biomarker validated to tell you 'stop now' for TB-500 specifically, so this is judgment-based, not data-based. This is also where sourcing quality intersects with cycle safety. A 2017 analytical chemistry paper on adsorption effects found that TB-500 and other doping-relevant peptides can behave unpredictably in solution and during handling, which is a chemistry problem, but it's also a practical reminder that compounding quality, storage, and reconstitution technique affect what's actually going into your body during a cycle ^[14]. Poor storage or a bad reconstitution can change what you're injecting without you knowing it. For the storage side of this, see TB-500 storage and shelf life, and for injection technique that reduces site-reaction risk, TB-500 how to inject.

What's the bottom line on choosing a cycle length?

If you're going to use a TB-500/BPC-157 blend at all, a 4-8 week loading and maintenance structure with a break afterward is the convention you'll find almost everywhere, and it's a reasonable starting point precisely because it's conservative and widely repeated, not because a trial validated it. What you should not do is treat any specific week count as clinically proven. The current published record, across the orthopaedic reviews ^[1][2], the safety review ^[5], and the analytical chemistry work on the molecule itself ^[3][4], supports one clear conclusion: TB-500 research is real and active, but it's preclinical-heavy and thin on controlled human dosing trials. Cycle length numbers you see quoted are working conventions from compounding practice, not FDA label instructions. If you want the provider-reviewed route rather than guessing at a protocol from a forum thread, that's the practical next step, working with a source that connects you to a licensed prescriber and a compounding pharmacy fulfilling a BPC-157/TB-500 blend rather than an unregulated vial with no chain of custody.

Frequently asked questions

How long should a TB-500 cycle last?

Most commonly cited protocols run 4-8 weeks of loading and maintenance dosing, followed by a break. This is a compounding-pharmacy and clinic convention, not a number established by a controlled human trial, so treat it as a starting framework rather than a proven optimal duration.

Can you run TB-500 continuously without breaks?

There's no published human trial comparing continuous to cycled TB-500 dosing. Most protocols include a 4-6 week break based on general peptide-dosing practice borrowed from other compounds, not TB-500-specific evidence. Running continuously is unstudied territory rather than a validated approach.

Is TB-500 the same thing as thymosin beta-4?

No. Thymosin beta-4 is the natural 43-amino-acid protein found in mammalian cells. TB-500 is a synthetic product marketed to mimic an active fragment of it, and analytical chemistry work has specifically characterized the distinct fragment found in commercial TB-500 products, confirming they aren't identical molecules.

How long until TB-500 starts working?

Anecdotal reports describe subjective changes around 2-4 weeks, with more noticeable effects reported by weeks 6-8. This comes from self-report, not measured clinical outcomes. Preclinical wound-healing screening exists in rat and in vitro models, but that timeline doesn't reliably translate to a human injury recovery calendar.

Does WADA prohibit TB-500?

Yes, TB-500 and thymosin beta-4-related peptides fall under WADA's Prohibited List, and multiple analytical chemistry studies have built detection methods specifically for it in human and equine doping control, confirming testers treat it as an active detection target.

Can you buy TB-500 by itself?

No. TB-500 is dispensed as a BPC-157/TB-500 blend, not as a standalone product, through the legitimate provider-reviewed route. Anyone selling isolated TB-500 as a single-ingredient product is operating outside that structure.

Is TB-500 FDA approved?

No. TB-500 doesn't appear in the FDA's Drugs@FDA database of approved products, and it isn't on FDA's current bulk drug substances lists for 503A or 503B compounding, which puts it in a regulatory gray zone rather than an approved-and-labeled category.

What happens if a TB-500 cycle runs longer than 8 weeks?

There's no published human safety data for extended cycles beyond the common 6-8 week window. The available safety literature on peptides like TB-500 is described as largely extrapolated from animal and in vitro work, so longer cycles are unstudied rather than proven safe.

Should you cycle TB-500 differently if stacking with BPC-157?

Not really, in practice, because TB-500 is already dispensed as a combined blend rather than sold alone. Cycle length guidance you see is for the blend itself. Neither peptide individually has a human trial establishing an ideal combined cycle length.

How do you know when to stop a TB-500 cycle early?

Stop if you notice unexpected injection site reactions, systemic symptoms like fever or unusual fatigue, or no subjective change by the midpoint of your planned cycle. There's no validated biomarker or test that tells you to stop; this is judgment-based monitoring, not data-driven.

Does cycle length affect detection risk for athletes?

Not meaningfully. Any use within a testable window creates exposure risk under WADA rules, regardless of how long the cycle runs. Analytical methods exist specifically to detect TB-500 in urine and plasma, so shortening a cycle doesn't meaningfully reduce detection risk.

Is there an official recommended TB-500 dosing schedule?

No official, FDA-labeled dosing schedule exists because TB-500 isn't an approved drug. What circulates as 'standard' protocols come from compounding pharmacies and clinics, based on practical convention and preclinical dosing patterns, not from a completed clinical trial establishing dose or duration.

Sources

1. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026: Review of therapeutic peptides in orthopaedics, including regenerative peptides like TB-500/BPC-157, discusses applications, challenges, and gaps between marketed use and human clinical evidence.
2. The American Journal of Sports Medicine, 2026: Primer for orthopaedic and sports medicine physicians on injectable peptide therapy, noting clinical use is ahead of the formal evidence base for dosing standards.
3. Drug Testing and Analysis, 2012: Study synthesizes and characterizes the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500 products, confirming TB-500 is a distinct fragment, not native thymosin beta-4.
4. Journal of Chromatography B, 2024: Method developed to simultaneously quantify TB-500 and its metabolites in vitro and in rats via UHPLC-Q-Exactive Orbitrap MS/MS, with wound-healing activity screening in vitro.
5. Sports Medicine (Auckland, N.Z.), 2026: Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries finds evidence for peptides like TB-500 is overwhelmingly preclinical.
6. Frontiers in Aging, 2026: Review of therapeutic peptides in gerontology notes dosing schedule optimization remains an active, unresolved mechanistic question across peptide classes.
7. Drugs@FDA, FDA-approved drug products database: TB-500 does not appear as an FDA-approved drug product in the Drugs@FDA database.
8. FDA, bulk drug substances nominated for use in compounding (current list): TB-500 is not on FDA's current list of bulk drug substances nominated and permitted for use in 503A compounding.
9. 21 CFR 216.24, the 503B Bulks List: Defines the bulk drug substances list applicable to 503B outsourcing facility compounding, which TB-500 is not included on.
10. 21 U.S.C. 353a, pharmacy compounding: Establishes the statutory conditions under which licensed pharmacists may compound drugs for individual patients under Section 503A.
11. 21 CFR 216.23, the final 503A Bulks List: Defines the bulk drug substances permitted for use in 503A compounding, the regulatory reference point for whether a substance can legally be compounded.
12. Journal of Chromatography A, 2012: Developed an LC-MS method for doping control detection of TB-500 in equine urine and plasma.
13. Journal of Pharmaceutical and Biomedical Analysis, 2014: Reviews analytical approaches for detecting emerging therapeutics and non-approved drugs, including TB-500, in human doping controls.
14. Analytical Biochemistry, 2017: Studied adsorption effects of doping-relevant peptides including TB-500 during sample handling, relevant to detection and to compounding/reconstitution quality.
15. Drug Testing and Analysis, 2016: Developed solid-phase extraction methods for isolating small bioactive peptides, including TB-500-class molecules, from human urine for doping analysis.
16. Journal of Peptide Science, 2015: Describes in vitro model systems used to study metabolism of small peptide hormones like TB-500 for sport drug testing purposes.